Clene Nanomedicine Inc

1 (801) 676-9695


Clene’s technology addresses neurodegenerative diseases to improve cellular bioenergetic function with nanocatalysts. Current Phase 2 studies include treatment of multiple sclerosis, Parkinson’s disease, and amyotrophic lateral sclerosis (Lou Gehrig’s disease)–neurodegenerative diseases with high unmet medical need. This approach may have broad applications across therapeutic areas with impaired bioenergetics. Founded in 2013, Clene is based in Salt Lake City with R&D and manufacturing operations located in Maryland.


Date Founded:


Company Size:


TechBuzz Articles:

Clene Nanomedicine Raises $42.5 Million for Novel Treatment of ALS, MS, Parkinson’s Disease, Mark Tullis, August 28, 2020

Buzzworthy Mentions:

Clene Announces Phase II Clinical Trial Results, November 5th, 2021

Clene Receives Award from US National Academy of Medicine, May 21st, 2021


Our mission is to be a catalyst for the success of the Utah tech and startup ecosystem.

              Google News

All contents © 2024 IsoTalent Inc. All rights reserved.

TechBuzz is an IsoTalent company

Terms of Use and Privacy Policy

Newsletter - Sign up to receive TechBuzz News daily